H.C. Wainwright Downgrades Shattuck Labs (STTK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TD Cowen Reiterates Buy Rating on Shattuck Labs (STTK)
October 1, 2024 9:28 AM EDTTD Cowen analyst Marc Frahm reiterated a Buy on Shattuck Labs (NASDAQ: STTK).
The analyst commented, "STTK has discontinued the SL-172154 program in HR-MDS/AML based on uncompelling OS separation vs. historical controls. The company is pivoting to a series of anti-DR3... More
Shattuck Labs (STTK) Provides Company Update and Announces SL-325
October 1, 2024 6:32 AM EDTShattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The Company will turn its focus to SL-325, its DR3 antagonist antibody, and plans initial clinical development in patients with IBD, where TL1A/DR3 blocking antibodies have demonstrated compelling monotherapy efficacy.
We are disappointed that the promising complete remission rates we... More
